Literature DB >> 3894129

Clinical predictors of retinopathy and its progression in patients with type I diabetes during CSII or conventional insulin treatment.

M A Testa, J E Puklin, R S Sherwin, D C Simonson.   

Abstract

Data from 70 type I diabetic patients with nonproliferative retinopathy participating in a multicenter clinical trial of control and complications were analyzed to test for associations of clinical variables with baseline levels and 8-mo changes in retinopathy. Predictor variables included age, duration of diabetes, systolic blood pressure, inpatient and outpatient plasma glucose levels, glycosylated hemoglobin (HbA1), M-values, serum cholesterol, serum triglycerides, and creatinine clearance. Retinopathy was assessed by fundus photography and graded at the Fundus Photograph Reading Center according to a detailed protocol. For the entire group, baseline retinopathy was positively correlated (P less than 0.05) with baseline systolic blood pressure, plasma glucose, HbA1, serum cholesterol, and duration of disease and negatively correlated with creatinine clearance. Conversely, during treatment, progression of retinopathy was negatively correlated (P less than 0.05) with mean levels during treatment of plasma glucose, HbA1, M-values, serum cholesterol, and with changes during treatment in plasma glucose and serum triglycerides. Two-group and three-group multivariate classification analysis of progression of retinopathy (improved or unchanged versus worsening--mild or moderate) indicated lower plasma glucose as the single best predictor of worsening of retinopathy (P less than 0.05), correctly classifying 71% of patients with positive progression. Decreased creatinine clearance during therapy was found to be the best discriminator between mild and moderate progression. Other multivariate models yielded specificity values of up to 71% and sensitivity values of up to 92%. We conclude that associations among clinical predictors and retinopathy during short-term glycemic control differ strikingly from those at baseline.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894129     DOI: 10.2337/diab.34.3.s61

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

Review 1.  Hypertension and diabetic retinopathy--what's the story?

Authors:  J T Gillow; J M Gibson; P M Dodson
Journal:  Br J Ophthalmol       Date:  1999-09       Impact factor: 4.638

Review 2.  Can retinopathy be prevented?

Authors:  B Weber; G Hövener; W Burger; R Hartmann; I Enders
Journal:  Indian J Pediatr       Date:  1989 Nov-Dec       Impact factor: 1.967

Review 3.  Diabetic control and microvascular complications: the near-normoglycaemic experience.

Authors:  K F Hanssen; K Dahl-Jørgensen; T Lauritzen; B Feldt-Rasmussen; O Brinchmann-Hansen; T Deckert
Journal:  Diabetologia       Date:  1986-10       Impact factor: 10.122

Review 4.  Pharmacoeconomics of diabetes surveillance and detection programmes.

Authors:  P D Home
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

Review 5.  Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence.

Authors:  Daniel J Moore; Justin M Gregory; Yaa A Kumah-Crystal; Jill H Simmons
Journal:  Vasc Health Risk Manag       Date:  2009-11-23

Review 6.  Management of Patients with Newly Diagnosed Diabetic Mellitus: Ophthalmologic Outcomes in Intensive versus Conventional Glycemic Control.

Authors:  Pun Yuet Lam; Shing Chuen Chow; Wai Ching Lam; Loraine Lok Wan Chow; Nicholas Siu Kay Fung
Journal:  Clin Ophthalmol       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.